The stock of Cipher Pharmaceuticals Inc (TSE:CPH) hit a new 52-week low and has $4.16 target or 10.00% below today’s $4.62 share price. The 9 months bearish chart indicates high risk for the $117.39M company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $4.16 price target is reached, the company will be worth $11.74 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 7,950 shares traded hands. Cipher Pharmaceuticals Inc (TSE:CPH) has declined 24.52% since March 31, 2016 and is downtrending. It has underperformed by 27.04% the S&P500.
Cipher Pharmaceuticals Inc (TSE:CPH) Ratings Coverage
Out of 2 analysts covering Cipher Pharmaceuticals (TSE:CPH), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cipher Pharmaceuticals has been the topic of 2 analyst reports since August 12, 2016 according to StockzIntelligence Inc. TD Securities maintained Cipher Pharmaceuticals Inc (TSE:CPH) on Friday, August 12 with “Buy” rating. On Friday, August 12 the stock rating was downgraded by GMP Securities to “Hold”.
More notable recent Cipher Pharmaceuticals Inc (TSE:CPH) news were published by: Prnewswire.com which released: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016, also Prnewswire.com with their article: “Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call” published on October 27, 2016, Prnewswire.com published: “Cipher Pharmaceuticals Inc. announces Sitavigâ„¢ accepted for review by Health …” on February 16, 2016. More interesting news about Cipher Pharmaceuticals Inc (TSE:CPH) were released by: Prnewswire.com and their article: “Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.” published on January 09, 2015 as well as Prnewswire.com‘s news article titled: “Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of …” with publication date: April 13, 2015.
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The company has a market cap of $117.39 million. The Firm has a portfolio of commercial and late-stage products. It currently has negative earnings. It operates in the specialty pharmaceuticals segment.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.